Addressing resistance to immune checkpoint inhibitor therapy - an urgent unmet need.
Fiche publication
Date publication
janvier 2021
Journal
Future oncology (London, England)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MALOUF Gabriel
Tous les auteurs :
Hu-Lieskovan S, Malouf GG, Jacobs I, Chou J, Liu L, Johnson ML
Lien Pubmed
Résumé
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of various cancers by reversing the immunosuppressive mechanisms employed by tumors to restore anticancer immunity. Although ICIs have demonstrated substantial clinical efficacy, patient response can vary in depth and duration, and many do not respond at all or eventually develop resistance. ICI resistance mechanisms can be tumor-intrinsic, related to the tumor microenvironment or patient-specific factors. Multiple resistance mechanisms may be present within one tumor subtype, or heterogeneity exists among patients with the same tumor type. Consequently, designing effective combination treatment strategies is challenging. This review will discuss ICI resistance mechanisms, and summarize findings from key preclinical and clinical trials of ICIs, to identify potential treatment strategies or pathways to overcome ICI resistance.
Mots clés
clinical trials, cytotoxic T-lymphocyte antigen-4, immune checkpoint inhibitor, mechanism, preclinical, programmed cell death protein 1, resistance
Référence
Future Oncol. 2021 Jan 21;: